Glucosamine & ChondroitinSulfate / hydrochloride · 4 claims

A network meta-analysis restricted to trials of more than 200 patients found pain differences versus placebo of −0.4 cm for glucosamine, −0.3 cm for chondroitin and −0.5 cm for the combination on a 10 cm scale. The minimal clinically important difference was prespecified at −0.9 cm. None of the credible intervals crossed it.

GAIT — a 24-week NIH-sponsored randomised trial with both placebo and celecoxib arms — found glucosamine and chondroitin alone or combined did not reduce pain effectively in the overall group. A more recent network meta-analysis of 30 RCTs and 5,265 patients found that apart from a few combination arms, none of the interventions met the clinical threshold for overall pain reduction.

• MetaWandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis BMJ 2010 · trials over 200 patients · MCID prespecified at −0.9 cm
• RCTClegg DO, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis (GAIT) N Engl J Med 2006 · doi 10.1056/NEJMoa052771 · NIH-sponsored, 24 weeks

Changes in minimal joint space width were all minute, with 95% credible intervals overlapping zero. The reviewers concluded that glucosamine, chondroitin and their combination do not reduce joint pain or affect joint space narrowing, and recommended that health authorities and insurers should not cover them.

This is the structural claim — the idea that these supplements rebuild or protect cartilage rather than just dulling pain. It is the reason the category exists and it is the claim with the least support.

• MetaWandel S, et al. Joint space width secondary outcome BMJ 2010 · all differences minute, credible intervals overlapping zero

The network meta-analysis tested this directly: industry-independent trials showed smaller effects than commercially funded trials, P=0.02 for interaction.

A 2024 network meta-analysis of 30 RCTs found the same problem in its risk-of-bias assessment. High risk of bias was mostly attributable to industry-funded studies and missing conflict of interest statements — 17 of 24 studies, 70.8%.

This is the most transferable finding on the page. When independent and commercial trials of the same product disagree systematically, the gap between them is a measurement of the funding effect, and it applies well beyond this supplement.

• MetaWandel S, et al. Industry independence interaction test BMJ 2010 · P=0.02 for interaction
• MetaSumsuzzman DM, et al. Comparative efficacy of glucosamine-based combination therapies in alleviating knee osteoarthritis pain J Clin Med 2024;13(23):7444 · 30 RCTs, 5,265 patients · 17/24 studies flagged for industry funding or missing COI

GAIT’s exploratory analyses suggested the glucosamine-chondroitin combination may be effective in the subgroup of patients with moderate-to-severe knee pain, having found nothing in the overall population.

Subgroup findings inside null trials are the single most common source of claims that later fail to replicate. It is worth reporting because it is the strongest thing anyone can honestly say for this category — and worth labelling clearly as what it is.

• RCTClegg DO, et al. GAIT exploratory subgroup analysis N Engl J Med 2006 · moderate-to-severe pain subgroup